Related Experiment Video
Updated: Aug 1, 2026
07:20
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
Interleukin-2 therapy for advanced chronic myeloid leukemia
M Goodman1, N Spector, G Rodrigues
1Hematology-Oncology Division of the University of Miami School of Medicine's Sylvester Comprehensive Cancer Center, FL 33136, USA.
Leukemia
|November 21, 1998
Summary
Interleukin-2 (IL-2) shows promise in treating advanced chronic myeloid leukemia (CML), extending survival beyond standard therapies. This approach offers a new avenue for patients with advanced CML, with minimal toxicity.
Area of Science:
- Oncology
- Immunology
Background:
- Chronic myeloid leukemia (CML) typically has a median survival of 6 years.
- Advanced CML (blast or accelerated phase) has limited treatment options and a poor prognosis, with a mean survival of 4 months.
Observation:
- Four patients with advanced CML (three blast phase, one accelerated phase) were treated with interleukin-2 (Proleukin).
- This cohort experienced a mean survival of 22 months, with two patients surviving beyond 25 months.
Findings:
- Interleukin-2 therapy resulted in a mean survival of 22 months (range 9-35 months) for advanced CML patients.
- One patient achieved a complete cytogenetic response, and another a partial response.
- Treatment with interleukin-2 was well-tolerated, with minimal toxicity and no discontinuations.
Implications:
- Interleukin-2 may offer a survival benefit for patients with advanced CML who have failed or progressed on standard therapies.
- Further investigation into IL-2 as a treatment for advanced CML is warranted.
- The observed minimal toxicity suggests IL-2 could be a viable option in this patient population.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.